Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company specializing in the development of prescription therapeutics for autoimmune, inflammatory, and debilitating diseases. Their product portfolio includes sofpironium bromide, BBI-02, and BBI-10, targeting primary axillary hyperhidrosis, autoimmune and inflammatory diseases, and rare genetic diseases. The company generates revenue through the development and commercialization of these therapeutics, leveraging license and collaboration agreements with industry partners. With a focus on advancing next-generation kinase inhibitors, Fresh Tracks Therapeutics aims to address unmet medical needs and drive growth through the successful introduction of innovative treatments to the market.

Products

• Sofpironium bromide

• BBI-02

• BBI-10

• Next-generation kinase inhibitors